Implementing effectiveness research and improving care for schizophrenia in real-world settings

American Journal of Managed Care

Volumn 5, Issue SPEC. ISS., 1999, Pages

  Buckley, Peter F ^a,d   Miller, Alexander ^b,c   Chiles, John A ^b   Sajatovic, Martha ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c San Antonio State Hospital   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; QUETIAPINE; RISPERIDONE; RITONAVIR; SAQUINAVIR; THIORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE;

AGRANULOCYTOSIS; ARTICLE; COST CONTROL; CRIMINAL JUSTICE; DROWSINESS; DRUG COST; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE POLICY; HUMAN; MENTAL HEALTH SERVICE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA; COMORBIDITY; ECONOMICS; HEALTH CARE QUALITY; INSURANCE; METHODOLOGY; OUTCOME ASSESSMENT; PRISONER; STANDARD; UNITED STATES; CLINICAL PRACTICE; COGNITIVE DEFECT; COST OF ILLNESS; HEALTH INSURANCE; MENTAL HEALTH CARE; SOMNOLENCE;

ANTIPSYCHOTIC AGENTS; COMORBIDITY; DRUG COSTS; HUMANS; INSURANCE COVERAGE; MENTAL HEALTH SERVICES; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES; PRISONERS; QUALITY ASSURANCE, HEALTH CARE; SCHIZOPHRENIA; UNITED STATES;

EID: 0033603085     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Tamminga CA. The promise of new drugs for schizophrenia treatment. Can J Psychiatry 1997;42:265-273.
2. Buckley PF. Treatment of schizophrenia: Let's talk dollars and sense. Am J Managed Care 1998;4:369-383.
3. Wells KB. Treatment research at the crossroads: The scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999;156:5-10.
4. Mueser KT, Bellack AS. Psychotherapy for schizophrenia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Cambridge, MA: Blackwell Science Ltd; 1995:626-648.
5. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. Arch Gen Psychiatry 1997;54:453-458.
6. National Plan for Schizophrenia Research. Washington, DC: US Dept of Health and Human Services; 1988. DHHS publication ADM 90-1683.
7. Freese F. Advocacy, support, consumerism and the challenges in schizophrenia. Psychiatr Clin North Am 1998;21:233-249.
8. Lebowitz BD, Rudorfer MV. Treatment research at the millennium: From efficacy to effectiveness [guest editorial]. J Clin Psychopharmacol 1998;18:1.
9. Lehman AF, Steinwachs DM (PORT co-investigators). Translating research into practice: The schizophrenia PORT treatment recommendations. Schizophr Bull 1998;24:1-10.
10. National Alliance for the Mentally Ill. National report card. Arlington, VA: National Alliance for the Mentally Ill; 1998.
11. Mahoud R. A naturalistic, 1 year comparative study of risperidone and conventional antipsychotics. Paper presented at: Annual Meeting of the American Psychiatric Association; May 1998; Toronto, Canada.
12. Fichtner CG, Luchins DJ, Malan RD, et al. Real-world pharmacotherapy with novel antipsychotics. J Prac Psychiatry Behavioral Health 1999;5:37-43.
13. National Alliance for the Mentally Ill. Consumer survey. Arlington, VA: National Alliance for the Mentally Ill; 1998.
14. Smith TE, Docherty JP. Standards of care and clinical algorithms for treating schizophrenia. Psychiatr Clin North Am 1998;21:203-220.
15. Frances A, Docherty JP, Kahn DA, et al. The Expert Consensus Guideline series. Treatment of schizophrenia. J Clin Psychiatry 1996;57(suppl):1-59.
16. Herz MI, Liberman RP, Lieberman JA, et al. American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(suppl):1-63.
17. Bailey L, Crismon ML, Dopheide JA, et al. Management of schizophrenia. In: Manolakis P, ed. APhA Guide to Drug Treatment Protocols: A Resource for Creating and Using Disease Specific Pathways. Washington, DC: American Pharmaceutical Association; 1997:SCZ-i-SCZ-8.
18. Altamura AC, Barnas C, Bitter I, et al. Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy. Int J Psychiatry Clin Pract 1997;1:S25-S30.
19. Veterans Health Administration. Clinical Guidelines for Management of Persons with Psychosis. Washington, DC: Office of Performance Management, VHA Headquarters; 1997.
20. Gilbert DA, Altshuler KZ, Rago WV, et al. Texas Medication Algorithm Project, 1: Definitions, rationale and methods to develop medication algorithms. J Clin Psychiatry 1998;59:345-351.
21. Kahn D, Docherty J, Carpenter D, et al. Consensus methods in practice guideline development: A review and description of a new method. Psychopharmacol Bull 1997;33:631-639.
22. Frances A, Kahn D, Carpenter D, et al. A new method of developing expert consensus practice guidelines. Am J Managed Care 1998;4:1023-1029.
23. Persons JB, Beck AT. Should clinicians rely on expert opinion or empirical findings? Am J Managed Care 1998;4:1051-1054.
24. Chiles JA, Miller AL, Crismon ML, et al. The Texas Medication Algorithm Project: Development and implementation of the schizophrenia algorithm. Psychiatr Serv 1999;50:69-74.
25. Rush AJ, Rago WV, Crismon ML, et al. Medication treatment of the severely and persistently mentally ill: The Texas Medication Algorithm Project. J Clin Psychiatry. In press.
26. Miller A, Chiles JA, Crimson ML, et al. The Texas Medication Algorithm. Paper presented at: Collegium Internationale Neuro-Psychopharmacologicum; July 1998; Glasgow, Scotland.
27. Trivedi MH, Crismon LM, Pigott T, et al. Texas Medication Algorithm Project: Depression module. Paper presented at: Annual Meeting of the American College of Neuropsychopharmacology; December 1998; Puerto Rico.
28. Committee on the Care of Severely Chronically Mentally Ill Veterans. Interim report on the deinstitutionalization of patients with psychoses. Washington, DC: Veterans Administration; 1998.
29. Jemelka R, Trupin E, Chiles JA. The mentally ill in prisons: A review. Hosp Community Psychiatry 1989;40:5-9.
30. Lamb HR, Weinberger LE. Persons with severe mental illness in jails and prisons: A review. Psychiatric Serv 1998;49:483-492.
31. Ruiz v Estelle, 503 F suppl 1265, 1323 (1980).
32. Drake RE, Mercer McFadden C, Mueser KT, et al. Review of integrated mental health and substance abuse treatment for patients with dual diagnosis. Schizophr Bull 1998;24:589-608.
33. Bartels SJ, Teague GB, Drake RE, et al. Substance abuse in schizophrenia: Service utilization and costs. J Nerv Ment Dis 1993;181:227-232.
34. Buckley PF. Substance abuse and schizophrenia - a review. J Clin Psychiatry 1998;59:26-30.
35. Zito JM. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatr Clin North Am 1998;21:181-202.
36. Mechanic D. Mental health services. The state of behavioral health in managed care. Am J Manag Care 1999'5:SP17-SP21.
37. Rabinowitz J, Bromet EJ, Lavelle J, et al. Relationship between type of insurance and care during the early course of psychosis. Am J Psychiatry 1998;155:1392-1394.
38. Wyatt RJ, Green MF. Early treatment and outcome in schizophrenia: A reanalysis of the Camarillo State Hospital data. Psychol Med 1997;27:1263-1271.
39. Druss BG, Rosenheck RA. Mental disorders and access to medical care in the United States. Am J Psychiatry 1998;155:1775-1777.
40. Adityanjee, Pelonero AL. Prescribing risperidone. Psychiatr Serv 1995;46:291-292.
41. Klausner M, Bracher M. Risperidone guidelines. Psychiatr Serv 1995;46:950-951.